Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
GT Biopharma (GB:0RU9)
LSE:0RU9
GT Biopharma (0RU9) Share Price & Analysis
0 Followers
0RU9 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€25.16 - €25.16
Previous Close€25.16
Volume0.00
Average Volume (3M)N/A
Market Cap
€9.15M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)-92.4
BetaN/A
Next Earnings
Mar 27, 2024EPS Estimate
-€0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.56Price Target Upside-81.86% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
GT Biopharma News
Ownership Overview
0.00% Insiders
3.25% Mutual Funds
3.17% Other Institutional Investors
93.58% Public Companies and
Individual Investors
0RU9 FAQ
What was GT Biopharma’s price range in the past 12 months?
GT Biopharma lowest share price was €25.16 and its highest was €25.16 in the past 12 months.
What is GT Biopharma’s market cap?
Currently, no data Available
When is GT Biopharma’s upcoming earnings report date?
GT Biopharma’s upcoming earnings report date is Mar 27, 2024 which is in 119 days.
How were GT Biopharma’s earnings last quarter?
GT Biopharma released its earnings results on Nov 01, 2023. The company reported -€0.055 earnings per share for the quarter, beating the consensus estimate of -€0.078 by €0.023.
Is GT Biopharma overvalued?
According to Wall Street analysts GT Biopharma’s price is currently Overvalued.
Does GT Biopharma pay dividends?
GT Biopharma does not currently pay dividends.
What is GT Biopharma’s EPS estimate?
GT Biopharma’s EPS estimate is -€0.08.
How many shares outstanding does GT Biopharma have?
GT Biopharma has 41,419,000 shares outstanding.
What happened to GT Biopharma’s price movement after its last earnings report?
GT Biopharma reported an EPS of -€0.055 in its last earnings report, beating expectations of -€0.078. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of GT Biopharma?
Currently, no hedge funds are holding shares in GB:0RU9
---
GT Biopharma Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€4.56 (-81.86% Downside)
€4.56 (-81.86% Downside)
News Sentiment
Neutral
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-87.97%
12-Months-Change
Fundamentals
Return on Equity
-78.73%
Trailing 12-Months
Asset Growth
-23.36%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
GT Biopharma
GT Biopharma, Inc. is engages in the development and commercialization of novel immuno-oncology products. Its products include OXS-1550, OXS-1650, OXS-3550, OXS-4550, OXS-1750, OXS-1950, and OXS-2050. The company was founded in 1965 and is headquartered in Westlake Village, CA.
---
---